Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Buys 15,000 Shares of Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Seth Lederman acquired 15,000 shares of the business’s stock in a transaction dated Wednesday, March 18th. The stock was bought at an average cost of $14.89 per share, with a total value of $223,350.00. Following the acquisition, the chief executive officer owned 15,001 shares in the company, valued at $223,364.89. The trade was a 1,500,000.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Tonix Pharmaceuticals Stock Down 5.1%

Shares of NASDAQ:TNXP traded down $0.77 during midday trading on Wednesday, hitting $14.19. The stock had a trading volume of 326,284 shares, compared to its average volume of 377,729. The company has a market cap of $190.15 million, a P/E ratio of -0.99 and a beta of 1.88. Tonix Pharmaceuticals Holding Corp. has a 12 month low of $13.07 and a 12 month high of $69.97. The business’s 50-day simple moving average is $15.61 and its 200-day simple moving average is $18.60.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($3.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.16) by ($0.82). The firm had revenue of $5.39 million for the quarter, compared to the consensus estimate of $2.97 million. Tonix Pharmaceuticals had a negative return on equity of 60.15% and a negative net margin of 946.22%. As a group, equities analysts predict that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current year.

Key Tonix Pharmaceuticals News

Here are the key news stories impacting Tonix Pharmaceuticals this week:

• Positive Sentiment: Management is increasing visibility to investors and partners — CEO Seth Lederman will present at BIO‑Europe Spring 2026 next week, which can help broaden institutional/partner interest and licensing visibility. Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
• Positive Sentiment: Scientific visibility: Tonix announced an oral presentation and two poster presentations on its preclinical immuno‑oncology portfolio at the AACR Annual Meeting (April), signaling R&D progress that could de‑risk parts of the pipeline over time. Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
• Positive Sentiment: Investor outreach: Tonix participated in an OTC Markets / Zacks virtual investor presentation, which can help improve retail and small‑cap analyst awareness and potentially support liquidity. OTC Markets Hosts Virtual Investor Presentation with Dr. Seth Lederman
• Neutral Sentiment: Q4 results were mixed — revenue beat estimates but EPS missed, and early commentary highlighted emerging momentum for Tonmya (the company’s commercial product), which is constructive for revenue outlook but offset by substantial losses. Tonix Q4: Revenue Beat, EPS Miss, Early Signs Of Tonmya Momentum
• Negative Sentiment: Noble Financial’s updates are mixed but skew negative overall: while the firm raised near‑term (Q1 and Q2) EPS loss estimates modestly, it cut Q3/Q4 and pushed FY2026 loss forecasts wider (FY now $(8.72) vs prior $(8.01)), signaling expectations for continued large losses and potentially increased funding or dilution risk. (Market commentary summarizing Noble’s changes.) MarketBeat TNXP analyst coverage summary

Analyst Ratings Changes

TNXP has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research report on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $70.00.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Legal & General Group Plc bought a new position in shares of Tonix Pharmaceuticals in the second quarter valued at about $25,000. Strs Ohio boosted its holdings in shares of Tonix Pharmaceuticals by 9.9% during the 4th quarter. Strs Ohio now owns 7,800 shares of the company’s stock worth $122,000 after buying an additional 700 shares during the period. Ameritas Investment Partners Inc. acquired a new position in Tonix Pharmaceuticals in the 2nd quarter valued at about $28,000. Rhumbline Advisers grew its stake in Tonix Pharmaceuticals by 8.0% in the 3rd quarter. Rhumbline Advisers now owns 12,206 shares of the company’s stock valued at $295,000 after buying an additional 908 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in Tonix Pharmaceuticals by 32.7% in the 3rd quarter. Bank of America Corp DE now owns 4,651 shares of the company’s stock valued at $112,000 after acquiring an additional 1,146 shares during the period. 82.26% of the stock is owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.